Centogene Announces Receipt of Nasdaq Delisting Notice

Notice of Non-Compliance and Intention to Request a Hearing

August 7, 2024

ROSTOCK, Germany and BERLIN -- CENTOGENE NV (Nasdaq: CNTG), a leading provider of genetic testing and analysis services, today announced that it has received a notice from Nasdaq ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of $1.00 per share for at least 10 consecutive business days.

The notice states that the Company has 45 days to submit a plan to Nasdaq outlining how it intends to regain compliance with the minimum bid price requirement. CENTOGENE intends to request a hearing with Nasdaq to discuss the matter and provide its plan to regain compliance.

The Company remains committed to working with Nasdaq to regain compliance with all applicable listing requirements. CENTOGENE believes that its strong fundamentals and long-term growth prospects will enable it to meet Nasdaq's requirements and continue to be listed on the Nasdaq Global Market.

About CENTOGENE

CENTOGENE is a global leader in rare disease diagnostics and genomic profiling, committed to providing patients and their families with comprehensive care and access to life-changing treatments. With a unique network of leading medical institutions, CENTOGENE combines scientific expertise with advanced genomic technologies to achieve its mission of improving the lives of patients with rare diseases.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements about the Company's plans, strategies, and expectations for the future, including its intention to request a hearing with Nasdaq. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release include, but are not limited to, the Company's ability to regain compliance with Nasdaq's minimum bid price requirement, the outcome of any hearing with Nasdaq, and the Company's ability to continue as a publicly traded company. The Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.